BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BNTX BioNTech SE

盘前交易 11-10 05:05:25 EST

87.51

+0.00

0.00%

盘前86.61

-0.90-1.03%

04:55 EST

最高88.78	最低86.56	成交量114.29万
今开87.76	昨收87.51	日振幅2.54%
总市值217.02亿	流通市值92.76亿	总股本2.48亿
成交额1.00亿	换手率1.08%	流通股本1.06亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BNTX","market":"US","secType":"STK","nameCN":"BioNTech SE","latestPrice":87.51,"timestamp":1794258000000,"preClose":87.51,"halted":0,"volume":1142936,"hourTrading":{"tag":"盘前","latestPrice":86.61,"preClose":87.51,"latestTime":"04:55 EST","volume":426,"amount":37090.01802,"timestamp":1794304514942,"change":-0.9,"changeRate":-0.010285,"amplitude":0.016324},"delay":0,"changeRate":0,"floatShares":106000000,"shares":248000000,"eps":-6.684866,"marketStatus":"盘前交易","change":0,"latestTime":"11-10 05:05:25 EST","open":87.76,"high":88.78,"low":86.56,"amount":100316041.32928,"amplitude":0.025369,"askPrice":86.84,"askSize":1,"bidPrice":86.5,"bidSize":225,"shortable":3,"etf":0,"ttmEps":-6.684866,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794321000000},"marketStatusCode":1,"adr":0,"adrRate":1,"listingDate":1570680000000,"exchange":"NASDAQ","adjPreClose":87.51,"preHourTrading":{"tag":"盘前","latestPrice":86.61,"preClose":87.51,"latestTime":"04:55 EST","volume":426,"amount":37090.01802,"timestamp":1794304514942,"change":-0.9,"changeRate":-0.010285,"amplitude":0.016324},"postHourTrading":{"tag":"盘后","latestPrice":88.44,"preClose":87.51,"latestTime":"19:38 EST","volume":68265,"amount":5974480.7,"timestamp":1794271083558,"change":0.93,"changeRate":0.010627,"amplitude":0.010627},"volumeRatio":1.113847318036883,"impliedVol":0.4978,"impliedVolPercentile":0.732},"requestUrl":"/m/hq/s/BNTX","defaultTab":"news","newsList":[{"id":"1120788080","title":"异动解读｜BioNTech SE盘中下跌5.06%，乳腺癌新药细分人群获益表述偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1120788080","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120788080?lang=zh_cn&edition=full","pubTime":"2026-11-06 04:39","pubTimestamp":1793911175,"startTime":"0","endTime":"0","summary":"11月6日，BioNTech SE盘中下跌5.06%，报86.17美元/股，成交额5816.14万美元。消息面上，公司最新表示，曲妥珠单抗帕米替康在HR+/HER2-low乳腺癌人群中的获益可能有限，正与DualityBio讨论BLA申报计划。此前该药III期试验虽达到无进展生存期主要终点，但总生存期数据尚未成熟，且公司曾披露少量严重及致命不良事件、间质性肺病发生率高于既往试验，令市场对其商业化预期与适用人群范围保持谨慎。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioNTech盘中下跌，乳腺癌新药获益表述偏谨慎","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177256321","title":"BioNTech第三季扭亏为盈，净利润达1.85亿欧元！上调全年营收指引，癌症新药研发取得进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1177256321","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177256321?lang=zh_cn&edition=full","pubTime":"2026-11-03 19:55","pubTimestamp":1793706932,"startTime":"0","endTime":"0","summary":"11月3日，德国生物科技公司 $BioNTech SE$公布2026年第三季度财报。尽管季度实现盈利，BioNTech今年前三季度累计仍录得11.68亿欧元净亏损，高于去年同期的8.31亿欧元。受第三季度业绩表现推动，BioNTech上调2026年全年营收指引，将预期区间由此前的16亿至19亿欧元收窄至17亿至19亿欧元，指引中值上调5000万欧元。在新药研发方面，BioNTech继续加快布局肿瘤治疗领域。财务状况方面，截至9月底，BioNTech持有现金、现金等价物及证券投资合计约161.64亿欧元。","market":"us","thumbnail":"https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcT3mn-e7odIjPDeezwb8ue0PaOaXvBNDTRxmhYGaftSFA&s=10","type":0,"news_type":0,"thumbnails":["https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcT3mn-e7odIjPDeezwb8ue0PaOaXvBNDTRxmhYGaftSFA&s=10"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"BioNTech第三季扭亏为盈，净利润达1.85亿欧元！上调全年营收指引，癌症新药研发取得进展","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2680728715","title":"BioNTech SE(BNTX.US)：启动股票回购计划，将在2027年5月前回购最多10亿美元的美国存托股份。","url":"https://stock-news.laohu8.com/highlight/detail?id=2680728715","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680728715?lang=zh_cn&edition=full","pubTime":"2026-11-03 19:46","pubTimestamp":1793706406,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MYLD","BK4551","SHRY","BK4585","SYLD","ACTV","DIVB","BK4548","BK4139","BK4535","BK4588","FYLD","BNTX","BUYB","PKW","LYLD","LGCF","BK4568","SPHQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680728714","title":"BioNTech SE(BNTX.US)第三季度营收12.892亿欧元。第三季度净利润1.845亿欧元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2680728714","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680728714?lang=zh_cn&edition=full","pubTime":"2026-11-03 19:46","pubTimestamp":1793706393,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4548","BK4535","BK4139","BK4588","BNTX","NBIE","BK4568","BK4585","FXE","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187737465","title":"异动解读｜BioNTech SE夜盘下跌6.39%，财报前市场聚焦收入恢复与管线不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=1187737465","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187737465?lang=zh_cn&edition=full","pubTime":"2026-11-03 10:37","pubTimestamp":1793673440,"startTime":"0","endTime":"0","summary":"11月3日，BioNTech SE夜盘下跌6.39%，报81.94美元/股，成交额4156.76美元。消息面上，公司将于当日披露最新季度业绩，市场一致预期季度营收约10.55亿欧元，同比增长9.81%，调整后每股收益约0.86欧元；但机构观点整体偏谨慎，短期更关注收入恢复、盈利弹性及mRNA管线对后续指引的影响。与此同时，公司近期管线消息分化：一项转移性乳腺癌三期试验达到主要终点，但披露存在少量严重及致命不良事件；另一项头颈癌试验未达无进展生存期主要终点，压制市场风险偏好。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"BioNTech夜盘下跌，财报与管线风险引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678126563","title":"小摩维持BioNTech(BNTX.US)“中性”评级：看好pumitamig联合B7-H3 ADC潜力，但关键数据读出仍需等到2028年后","url":"https://stock-news.laohu8.com/highlight/detail?id=2678126563","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678126563?lang=zh_cn&edition=full","pubTime":"2026-10-27 15:47","pubTimestamp":1793087234,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["JPO","LU1988902786.USD","IXG","XLF","LU0345770308.USD","BK4551","IYF","UYG","IE000BZT7R73.USD","FNCL","LU2456880835.USD","LU0203345920.USD","LU0882574139.USD","IE000SO60NU8.SGD","VFH","BNTX","LU1720051017.SGD","LU2430703095.HKD","IE00BDCRKT87.USD","LU1244550494.USD","IYG","IE0000B7K699.USD","LU1366192091.USD","LU2237443382.USD","FTXO","KBWB","LU0170899867.USD","LU1551013342.USD","LU0211326755.USD","LU0234572021.USD","LU2242649171.HKD","LU2023250330.USD","LU2357305700.SGD","LU0211328371.USD","LU0971096721.USD","LU0859254822.USD","LU0251132253.USD","JPMO","IE00B3S45H60.SGD","LU0265550946.USD","LU1261432733.SGD","LU2168563687.JPY","LU1116320737.USD","LU1267930490.SGD","TFNS","TRUF","LU0157215616.USD","LU2213496289.HKD","LU2552382058.USD","IE00B775SV38.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170970786","title":"财报前瞻 | BioNTech SE本季度营收预计约10.55亿欧元，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1170970786","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170970786?lang=zh_cn&edition=full","pubTime":"2026-10-27 08:54","pubTimestamp":1793062476,"startTime":"0","endTime":"0","summary":"BioNTech SE将于2026年11月03日发布最新季度业绩，市场聚焦收入恢复与盈利弹性，以及mRNA管线催化剂对短期指引的影响。市场一致预期本季度BioNTech SE营收约10.55亿欧元，同比增长9.81%；调整后每股收益约0.86欧元，同比增长504.81%；息税前利润约2.76千万欧元，同比增长290.60%。上一季度BioNTech SE营收1.06亿欧元，同比下降59.51%；毛利率8.14%；归属于母公司股东的净利润为-8.21亿欧元，净利率未披露；调整后每股收益为-3.24欧元，同比下降102.50%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | BioNTech SE本季度营收预计约10.55亿欧元，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100358215","title":"异动解读｜BioNTech SE夜盘上涨5.5%，乳腺癌联合疗法合作推进带动关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1100358215","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100358215?lang=zh_cn&edition=full","pubTime":"2026-10-26 08:17","pubTimestamp":1792973825,"startTime":"0","endTime":"0","summary":"10月26日，BioNTech SE夜盘上涨5.5%，报92.96美元，成交额541.0美元。推动异动的消息面，主要是公司近日宣布与吉利德科学合作，评估其实验药物pumitamig与Trodelvy联合作为晚期三阴性乳腺癌一线治疗方案。根据披露，BioNTech计划在获得监管批准后调整全球Ⅲ期ROSETTA Breast-01试验，以Trodelvy替代化疗；公司继续主导并赞助试验，吉利德负责供应药物。这将成为首个将pumitamig与抗体偶联药物联用的全球Ⅲ期研究，显示其肿瘤管线推进仍在延续。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"BioNTech夜盘上涨，乳腺癌联合疗法推进","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674896322","title":"前BioNTech高管带队，Bambusa Therapeutics(BBTX.US)冲刺纳斯达克，为湿疹药物试验“输血”","url":"https://stock-news.laohu8.com/highlight/detail?id=2674896322","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674896322?lang=zh_cn&edition=full","pubTime":"2026-10-10 14:05","pubTimestamp":1791612349,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Bambusa Therapeutics Inc.已提交首次公开募股申请，计划募集资金，用于开发湿疹及其他炎症性疾病治疗药物的临床试验。文件显示，联合创始人Shanshan Xu曾是BioNTech高管，实益持有Bambusa 21.5%的股份。截至6月底，Bambusa拥有7150万美元现金及等价物。Bambusa预计其股票将在纳斯达克全球精选市场交易，股票代码为BBTX。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4551","BNTX","BK4548","BK4588","BK4139","BK4585","BK4568","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158673114","title":"美股生物疫苗概念股盘中集体上扬，俄罗斯“不明原因肺炎”病例持续引发关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1158673114","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158673114?lang=zh_cn&edition=full","pubTime":"2026-10-09 21:59","pubTimestamp":1791554397,"startTime":"0","endTime":"0","summary":"10月9日，美股$生物(000504)$疫苗概念股盘中集体上扬，$诺瓦瓦克斯医药(NVAX)$涨超12%，$Moderna(MRNA)$涨超8%，$BioNTech SE(BNTX)$、Vaxcyte涨超4%。","market":"us","thumbnail":"https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNY","BK4533","GNOM","BK4588","LGHT","IDNA","BK4139","BK4551","WDNA","BNTX","BK4585","BK4547","BK4501","MRNX","BK4568","BK4532","BK4548","NVAX","BK4535","MRNA","BK4534","159657"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671262617","title":"辉瑞(PFE.US)、BioNTech(BNTX.US)、Moderna(MRNA.US)寻求驳回拜耳旗下孟山都mRNA专利诉讼遭法官拒绝","url":"https://stock-news.laohu8.com/highlight/detail?id=2671262617","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671262617?lang=zh_cn&edition=full","pubTime":"2026-09-29 10:28","pubTimestamp":1790648936,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4599","LU1023059063.AUD","LU1057294990.SGD","OZEM","IDNA","BK4585","MRNX","MRNY","LU0306806265.USD","SGXZ57979304.SGD","BK4551","BK4588","BK4568","BK4581","LU1894683348.USD","LU1883839398.USD","BK4534","SG9999003800.SGD","LU0289739699.SGD","BK4501","IE00BBT3K403.USD","IE000M9KFDE8.USD","BNTX","IE00BLSP4452.SGD","WDNA","LU0122379950.USD","SG9999001176.SGD","BK4550","GNOM","IE00B3T34201.USD","BK4592","LU0170899867.USD","MRNA","BK4139","LU0234572021.USD","LU1066051498.USD","0P6S.UK","IE00B19Z3581.USD","BK4007","IE0002270589.USD","LU0225284248.USD","SG9999013999.USD","LU0868494617.USD","IE00BLSP4239.USD","LU1894683264.USD","PFE","BK5011","LU0456855351.SGD","SG9999002224.SGD","BK4548","LU0321505868.SGD","BK4535","BK4532","LU1066053197.SGD","IE00B19Z3B42.SGD","LU0058720904.USD","BK4533","LGHT","LU0306807586.USD","LU2596442595.SGD","SG9999001176.USD","SG9999002232.USD","LU0985481810.HKD","LU0225771236.USD","LU0321505439.SGD","SG9999011175.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668901099","title":"ARISTA网络：大股东Andreas Bechtolsheim拟出售30万股，市值约5985.90万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668901099","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668901099?lang=zh_cn&edition=full","pubTime":"2026-09-18 06:38","pubTimestamp":1789684680,"startTime":"0","endTime":"0","summary":"南财智讯9月18日电，ARISTA网络（AristaNetworks,Inc.，纽约证券交易所：ANET）10%股东AndreasBechtolsheim提交Form144限制股出售声明。AndreasBechtolsheim拟出售30万股普通股，合计市值约5985.90万美元，拟出售日期为9月17日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609183877710385.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609183877710385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4548","BK4551","BK4535","BK4588","BK4568","BNTX","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141268762","title":"异动解读｜BioNTech盘前上涨超5%，肺癌候选药三期试验总生存期数据积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1141268762","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141268762?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:06","pubTimestamp":1789384003,"startTime":"0","endTime":"0","summary":"9月14日，BioNTech盘前上涨5.04%，报101.23美元/股，成交额116.56万美元。消息面上，BioNTech与OncoC4联合公布了PRESERVE-003三期临床试验第一阶段的更新数据，结果显示候选药物gotistobart在肺癌患者中展现出具有统计学意义的总生存期获益，生存期几乎翻倍。这一积极数据为BioNTech向肿瘤学领域转型提供了关键支撑。值得注意的是，BioNTech此前曾因终止结直肠癌二期试验导致股价大幅下挫，且二季度财报营收和盈利均不及预期，全年收入指引也遭下调。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BioNTech盘前上涨，肺癌候选药生存期数据积极","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667570696","title":"生存期几乎翻倍！BioNTech(BNTX.US)肺癌候选药PRESERVE-003后期试验告捷，肿瘤学转型再获关键支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=2667570696","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667570696?lang=zh_cn&edition=full","pubTime":"2026-09-14 18:26","pubTimestamp":1789381582,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","BK4551","BK4139","BK4588","BK4568","CANC","BNTX","BK4535","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667064657","title":"生存期几乎翻倍！BioNTech(BNTX.US)肺癌候选药PRESERVE-003后期试验告捷，肿瘤学转型再获关键支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=2667064657","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667064657?lang=zh_cn&edition=full","pubTime":"2026-09-14 18:26","pubTimestamp":1789381582,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，BioNTech周一表示，一项后期临床试验显示，其候选药物gotistobart在一种特定类型肺癌中，较标准治疗带来具有临床意义的总生存期获益。公司称，该试验为PRESERVE-003 III期临床试验，纳入的是在接受既往免疫治疗和化疗后疾病仍出现进展的鳞状非小细胞肺癌患者;与标准治疗化疗相比，gotistobart使生存期几乎翻倍。鳞状非小细胞肺癌约占所有肺癌病例的25%至30%，在非小细胞肺癌中属于侵袭性较强的亚型。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4551","BK4568","BK4588","BNTX","CANC","BK4548","BK4585","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192361867","title":"异动解读｜BioNTech盘中下跌5.08%，遭BMO下调评级至与大市同步","url":"https://stock-news.laohu8.com/highlight/detail?id=1192361867","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192361867?lang=zh_cn&edition=full","pubTime":"2026-09-08 23:37","pubTimestamp":1788881832,"startTime":"0","endTime":"0","summary":"9月8日，BioNTech盘中下跌5.08%，报98.485美元/股，成交额4746.28万美元。消息面上，BMO Capital Markets将BioNTech评级从\"跑赢大市\"下调至\"与大市同步\"，目标价由128美元下调至105美元，理由是近期上行空间有限、风险回报趋于平衡。BioNTech SE成立于2008年，专注于结合免疫学研究与mRNA等治疗平台，开发针对癌症和其他疾病的个体化免疫疗法。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioNTech遭下调评级，股价承压下探","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100460280","title":"美股生物医药股盘初走低，BioNTech跌超9%、Moderna跌近5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100460280","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100460280?lang=zh_cn&edition=full","pubTime":"2026-08-28 21:37","pubTimestamp":1787924271,"startTime":"0","endTime":"0","summary":"8月28日，美股生物医药股盘初走低，$BioNTech(BNTX)$跌超9%，公司宣布终止结直肠癌2期临床试验；$Moderna(MRNA)$跌近5%，$默沙东(MRK)$跌1.5%。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0208291251.USD","LU2125909593.SGD","BK4501","LU0130102774.USD","MRNA","IE00BJT1NW94.SGD","LGHT","LU1066053197.SGD","PAWZ","SG9999001440.SGD","BMED","LU1037948897.HKD","LU2089984988.USD","LU1929549753.HKD","LU1023059063.AUD","LU0211331839.USD","LU0965508806.USD","LU0861579265.USD","LU2023250504.SGD","161726","LU0985320562.USD","BK4550","LU1585245621.USD","LU2106854487.HKD","LU0234572021.USD","PPH","LU0265550359.USD","FTXH","LU0098860793.USD","LU1974910355.USD","LU1923622614.USD","LU1035773651.USD","IE00B1BXHZ80.USD","LU1941712348.USD","FHLC","LU0289739699.SGD","LU1989771016.USD","GNOM","LU2125909247.SGD","SG9999013999.USD","LU0689626769.HKD","BK4585","LU1201861249.SGD","HRTS","LU1934455863.HKD","RXL","LU1430594728.SGD","LU0432979614.USD","LU0124676726.USD","IYH","BK4581","LU0266013472.USD","BK4588","LU0980610538.SGD","IBBQ","LU1037948541.HKD","LU0203345920.USD","LU0058720904.USD","IXJ","LU1066051225.USD","LU2125154935.USD","LU0070302665.USD","IE00BLSP4452.SGD","BK4532","TRUH","SG9999001176.SGD","SG9999014559.SGD","LU1066051811.HKD","LU1934455277.USD","LU2433249047.HKD","IE0009355771.USD","LU1989772840.SGD","LU0965509010.AUD","VHT","LU0203347892.USD","IE00BBT3K403.USD","LU2324357040.USD","SGXZ57979304.SGD","MRNX","LU1699723380.USD","LU1941712264.USD","JDOC","LU0823416689.USD","LU0868494708.USD","LU2361045086.USD","LU1066051498.USD","SG9999014567.USD","LU0122379950.USD","BNTX","IE00BJJMRZ35.SGD","LU2491049909.HKD","LU2023250843.SGD","SG9999002224.SGD","LU0320765489.SGD","GDOC","LU1162221912.USD","LU1069347547.HKD","SG9999014575.USD","LU2461242641.AUD","BK4007","LU2468319806.SGD","SG9999015341.SGD","LU1093756325.SGD","BK4534","LU0130517989.USD","IE00BSNM7G36.USD","LU2360032135.SGD","LU2112291526.USD","LU1983299246.USD","MDTX","LU0477156953.USD","LU0942090050.USD","IDNA","IE00BLSP4239.USD","SG9999014542.SGD","IE000M9KFDE8.USD","XLV","MRK","LU0859254822.USD","PSYK","IE00B4R5TH58.HKD","LU2361044949.HKD","IE00BFTCPJ56.SGD","LU2357627491.SGD","BK4516","LU2491050154.USD","LU2361044865.SGD","LU1571399168.USD","BK4568","LU1917777945.USD","LU1989772923.USD","BK4548","LU1116320901.HKD","SG9999015358.SGD","XBI","LU2125154778.USD","LU2491050071.SGD","IE00B2B36J28.USD","LU0648001328.SGD","LU0965509283.SGD","LU0320765646.SGD","LU1093756168.USD","MRNY","LU1291159041.SGD","WDNA","SG9999002232.USD","IE0002141913.USD","LU0106261372.USD","LU0238689110.USD","LU0265550946.USD","LU1934455194.USD","BK4559","LU0006306889.USD","LU1061106388.HKD","BK4139","IHE","LU1116320737.USD","BK4551","SG9999001176.USD","BK4533","IE00BN8TJ469.HKD","LU0868494617.USD","LU1057294990.SGD","LU0965509101.SGD","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662096564","title":"美股三大股指涨跌互现，纳指跌 0.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662096564","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662096564?lang=zh_cn&edition=full","pubTime":"2026-08-28 21:32","pubTimestamp":1787923979,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据 Gate 行情数据显示，美股开盘，三大股指涨跌互现，道指涨 0.21%，标普 500 指数涨 0.05%，纳指跌 0.09%。\n\nBioNTech(BNTX.O) 跌约 8.7%，宣布终止结直肠癌 2 期临床试验。 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2286268","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JEPQ","GPIQ","QYLG","IYW","QQQE","QQQJ","QDTE",".IXIC","TECS","QQQA","BK4551","NDX","BK4585","QQQY","BK4588","BK4548","MNQmain","QQQM","TQQY","BK4568","PSQ",".HXC","BNTX","BK4139","ONEQ","NVIW.SI","QID","FTEC","BK4535","QLD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100503819","title":"异动解读｜BioNTech SE盘中下跌8.22%，终止癌症免疫疗法试验叠加新冠疫苗适用人群收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1100503819","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100503819?lang=zh_cn&edition=full","pubTime":"2026-08-28 21:32","pubTimestamp":1787923929,"startTime":"0","endTime":"0","summary":"8月28日，BioNTech SE盘中下跌8.22%，报99.11美元/股，成交额5648.04万美元。消息面上，公司宣布终止2期Autogene Cevumeran结直肠癌免疫疗法试验，该管线为公司mRNA肿瘤治疗领域的核心项目之一，终止意味着其从新冠疫苗向肿瘤免疫治疗转型的关键布局遭遇重大挫折。与此同时，辉瑞与BioNTech针对XFG变体的新冠疫苗虽获FDA批准，但适用范围仅限65岁及以上成年人和5至64岁高风险人群，较此前面向全人群接种的授权范围显著收窄，市场对其新冠疫苗收入前景进一步承压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"BioNTech重挫，终止癌症试验叠加疫苗受限","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199946302","title":"BioNTech SE宣布终止2期Cevumeran癌症免疫疗法试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1199946302","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199946302?lang=zh_cn&edition=full","pubTime":"2026-08-28 21:14","pubTimestamp":1787922863,"startTime":"0","endTime":"0","summary":"8月28日，BioNTech SE盘前暴跌逾14%，公司宣布终止2期Cevumeran癌症免疫疗法试验。","market":"us","thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"BioNTech SE宣布终止2期Cevumeran癌症免疫疗法试验","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biontech.com","stockEarnings":[{"period":"1week","weight":-0.0002},{"period":"1month","weight":-0.0975},{"period":"3month","weight":-0.057},{"period":"6month","weight":-0.0512},{"period":"1year","weight":-0.1515},{"period":"ytd","weight":-0.0808}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0332},{"period":"3month","weight":-0.0232},{"period":"6month","weight":0.014},{"period":"1year","weight":0.1218},{"period":"ytd","weight":0.1038}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BioNTech SE成立于2008年6月2日。该公司结合了数十年的免疫学，尖端治疗平台以及各种患者分析和生物信息学工具的开创性研究，开发针对癌症和其他疾病的个体化免疫疗法。该公司利用强大的新治疗机制，利用各种生物学靶点，利用每位患者免疫系统的力量，解决每位患者潜在疾病的独特分子特征。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.014337},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.037906},{"month":3,"riseRate":0.571429,"avgChangeRate":0.057688},{"month":4,"riseRate":0.428571,"avgChangeRate":0.076942},{"month":5,"riseRate":0.571429,"avgChangeRate":0.029093},{"month":6,"riseRate":0.571429,"avgChangeRate":0.037799},{"month":7,"riseRate":0.857143,"avgChangeRate":0.124155},{"month":8,"riseRate":0.571429,"avgChangeRate":-0.027067},{"month":9,"riseRate":0.285714,"avgChangeRate":0.012911},{"month":10,"riseRate":0.571429,"avgChangeRate":0.005477},{"month":11,"riseRate":0.75,"avgChangeRate":0.167884},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.033371}],"exchange":"NASDAQ","name":"BioNTech SE","nameEN":"BioNTech SE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BioNTech SE(BNTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BioNTech SE,BNTX,BioNTech SE股票,BioNTech SE股票老虎,BioNTech SE股票老虎国际,BioNTech SE行情,BioNTech SE股票行情,BioNTech SE股价,BioNTech SE股市,BioNTech SE股票价格,BioNTech SE股票交易,BioNTech SE股票购买,BioNTech SE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BioNTech SE(BNTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}